Biotech Values

[bellweather1]

TGTX Seeking Alpha Article/My Comment...

I'm posting my comment here because it's either not posted(or virtually inaccessible) at Seeking Alpha.

Seeking Alpha article:http://seekingalpha.com/article/2507195-tg-therapeutics-reaches-phase-3-special-protocol-assessment-faster-than-expected#comment-40433445

MY Comment:

Mrs. BullBear,

I guess your TGTX article is fair, as far as it goes(although I don't think you really need to tell us that clinical trial failure is a risk, do you?). But I'm afraid the biggest problem IMO, is that your article is so superficial in it's appreciation and value assessment of TGTX, that I have trouble understanding why you even wrote it.

For example, most observers would note that TGR-1202(TGTXs PI3K inhibitor) is
very likely to be a superior drug(due to it's much better toxicity and administration profile) compared to duvelisib, which ABBY just paid INFI approx. 800ml for(and that's not even including hefty future royalties).

This fact alone clearly suggests, TGTX, at its current Mkt cap of about 450ml, is seriously undervalued, seeing as the company, as you note, also has another likely best-in-class drug (TG-1101) on a fast track to approval in combination trials with one of the most important drugs in B-cell therapy(Imbruvica).

Just as importantly, however, also overlooked is that fact that if TGR-1202 and TG-1101(an anti CD20) both prove to be best-in-class (as is likely), they will become part of a wide range of combination therapies which would dramatically outstrip their utility and profitability as single drug therapies.

This of course, further suggests that the company is seriously undervalued and(as has been pointed out frequently), an obvious takeover target for a number of larger companies looking to bolster their B-cell combo assets as competition heats up in the sector.

Therefore, in summary, I was disappointed in your article because it missed the larger points(as has most of the market till very recently),that 1)TGTXs vision to produce the best drugs for B-cell combination therapy is the correct one, and, 2) it's ability to execute on that vision (with 2 seemingly best-in-class drugs), makes it a steal(at the current market cap).

Apparently, they only print favorable comments(lol)?

Regards,

bw